Additional Analyses Help Idorsia Secure English Funding For Chronic Insomnia Drug Quviviq
Executive Summary
Quviviq is to become the first dual orexin receptor antagonist available on the National Health Service. Just over 20,000 people in England could receive treatment with the drug in its first year, says the health technology assessment institute, NICE.